Adyn is a precision medicine company that develops personalized birth control methods. It provides medically actionable scientific insights and empowers individuals to proactively optimize their health—from birth control to fertility and beyond. The company’s first product, the Birth Control Optimization Test, is an at-home kit enabling users to collect both saliva and finger prick samples to measure hormone baseline levels and aims to assess genetic risk for blood clots and depression. Adyn’s technology then synthesizes a medical biography with side effect profiles of estrogens and progestins used in hormonal contraception. Elizabeth Ruzzo headquartered the company in Seattle, Washington in 2019 and is backed by Lux Capital, M13, Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, and Ascend VC.
